1- Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics.CA Cancer J Clin 2011Mar-Apr; 61(2): 69–90.
2- Wang N, Ma Q, Wang Y, Ma G, Zhai H. Cacy BP/SIP expression is involved in the clinical progression of breast cancer. World J Surg 2010Nov; 34(1): 2545–52.
3-Olopade OI, Grushko TA, Nanda R, Hou D. Advances in breast cancer: Pathways to personalized medicine. Clin Cancer Res 2008; 14: 7988–99.
4-Dickson C, Spencer-Dene B, Dillon C, Fantl V. Tyrosine kinasesignalling in breast cancer: fibroblast growth factors and their receptors. Breast Cancer Res 2000: 2: 191–6.
5- Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, Ballinger DG, "et al". Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007; 447:1087–93.
6-Hunter DJ, Kraft P, Jacobs KB, Cox DG, Yeager M, Hankinson SE, "et al". A genome-wide association study identifies alleles in FGFR2 ssociated with risk of sporadic postmenopausal breast cancer. Nat Genet 2007Jul; 39(7): 870–4.
7-MartinAJ, GrantA, Ashfield AM, Palmer CN, Baker L, Quinlan PR, "et al". FGFR2 protein expression in breast cancer:nuclearlocalisation and correlation with patient genotype. BMC Research Notes 2011Mar, 4(72): 1-7.
8-Tannheimer SL, Rehemtulla A, Ethier SP. Characterization of fibroblast growth factor receptor 2 overexpression in the human breast cancer cell line SUM-52PE. Breast Cancer Res 2000May; 2(4): 311-20.
9-Sun S, Jiang Y, Zhang G, Song H, Zhang X, Zhang Y, "et al". Increased expression of fibroblastic growth factor receptor 2 is correlated with poor prognosis in patients with breast cancer. J Surg Oncol 2012 Jun; 105(8): 773–9.